GW427353 (Solabegron), a novel, selective β3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 1, 2007, Pages 202-209

  Hicks, Alexandra ^a   McCafferty, Gerald P ^a   Riedel, Erin ^a   Aiyar, Nambi ^a   Pullen, Mark ^a   Evans, Christopher ^a   Luce, Trudy D ^a   Coatney, Robert W ^a   Rivera, Gian C ^a   Westfall, Timothy D ^a   Hieble, J Paul ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ACETIC ACID; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUPRANOLOL; CYCLIC AMP; ISOPRENALINE; SOLABEGRON;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLADDER; BLADDER MUSCLE; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG SCREENING; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MICTURITION REFLEX; MUSCLE RELAXATION; NONHUMAN; PRIORITY JOURNAL;

ACETIC ACID; ADRENERGIC BETA-AGONISTS; ANILINE COMPOUNDS; ANIMALS; BENZOIC ACIDS; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DISEASE MODELS, ANIMAL; DOGS; FEMALE; HUMANS; MUSCLE RELAXATION; MUSCLE, SMOOTH; RECEPTORS, ADRENERGIC, BETA-3; REFLEX; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; URINATION;

EID: 34548840602     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.125757     Document Type: Article

References (31)

1. Andersson KE and Wein AJ (2004) Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 56:581-631.
2. Baker JG (2005) The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol 144:317-322.
3. Biers SM, Reynard JM, and Brading AF (2006) The effects of a new selective beta 3 adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int 98:1310-1314.
4. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR Jr, and Trendelenburg U (1994) International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46:121-136.
5. Donckier JE, Massart PE, Van Mechelen H, Heyndrickx GR, Gauthier C, and Balligand JL (2001) Cardiovascular effects of beta 3-adrenoceptor stimulation in perinephritic hypertension. Eur J Clin Invest 31:681-689.
6. Elshourbagy NA, Korman DR, Wu H-L, Sylvester DR, Lee JA, Nuthalaganti P, Bergsma DJ, Kumar CS, and Nambi P (1993) Molecular characterization and regulation of human endothelin receptors. J Biol Chem 268:3873-3879.
7. Horinouchi T and Koike K (2001) Agonistic activity of SR59230A at atypical beta-adrenoceptors in guinea pig gastric fundus and duodenum. Eur J Pharmacol 416:165-168.
8. Hutchinson DS, Sato M, Evans BA, Christopoulos A, and Summers RJ (2005) Evidence for pleiotropic signaling at the mouse β3-adrenoceptor revealed by SR59230A [3-(2-ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino] -2S-2-propanol oxalate]. J Pharmacol Exp Ther 312:1064- 1074.
9. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
10. Kaidoh K, Igawa Y, Takeda H, Yamazaki Y, Akahane S, Miyata H, Ajisawa Y, Nishizawa O, and Andersson KE (2002) Effects of selective beta2 and beta3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol 168:1247-1252.
11. Larsen TM, Toubro S, van Baak MA, Gottesdiener KM, Larson P, Saris WH, and Astrup A (2002) Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr 76:780-788.
12. Li JH, Yasay GD, and Kau ST (1992) β-Adrenoceptor subtypes in the detrusor of guinea-pig urinary bladder. Pharmacology 44:13-18.
13. Manara L, Badone D, Baroni M, Boccardi G, Cecchi R, Croci T, Giudice A, Guzzi U, Landi M, and Le Fur G (1996) Functional identification of rat atypical betaadrenoceptors by the first beta 3-selective antagonists, aryloxypropanolaminotetralins. Br J Pharmacol 117:435-442.
14. Michel MC and Vrydag W (2006) α1-, α2- and β-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 147:S88-S119.
15. Nergardh A, Boreus LO, and Naglo AS (1977) Characterization of the adrenergic beta-receptor in the urinary bladder of man and cat. Acta Pharmacol Toxicol 40:14-21.
16. Nomiya M and Yamaguchi O (2003) A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 170:649-653.
17. Pietri-Rouxel F and Strosberg AD (1995) Pharmacological characteristics and species-related variations of beta 3-adrenergic receptors. Fundam Clin Pharmacol 9:211-218.
18. 3-adrenoceptors. J Cardiovasc Pharmacol 36:466-471.
19. Shen YT, Cervoni P, Claus T, and Vatner SF (1996) Differences in beta-3 adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. J Pharmacol Exp Ther 278:1435-1443.
20. Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, and Yamaguchi O (2007) Effect of (R)-2-(2- aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide YM178, a novel selective β3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642-647.
21. Takeda H, Igawa Y, Komatsu Y, Yamazaki Y, Akahane M, Nishizawa O, and Ajisawa Y (2000) Characterization of beta-adrenoceptor subtypes in the ferret urinary bladder in vitro and in vivo. Eur J Pharmacol 403:147-155.
22. Takeda H, Matsuzawa A, Igawa Y, Yamazaki Y, Kaidoh K, Akahane S, Kojima M, Miyata H, Akahane M, and Nishizawa O (2003) Functional characterization of β-Adrenoceptor subtypes in the canine and rat lower urinary tract. J Urol 170:654-658.
23. Takeda H, Yamazaki Y, Akahane M, Akahane S, Miyata H, Igawa Y, and Nishizawa O (2002a) Characterization of beta-adrenoceptor subtype in bladder smooth muscle in cynomolgus monkey. Jpn J Pharmacol 88:108-113.
24. Takeda H, Yamazaki Y, Igawa Y, Kaidoh K, Akahane S, Miyata H, Nishizawa O, Akahane M, and Andersson KE (2002b) Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol Urodyn 21:558-565.
25. Tavernier G, Galitzky J, Bousquet-Melou A, Montastruc JL, and Berlan M (1992) The positive chronotropic effect induced by BRL 37344 and CGP 12177, two beta-3 adrenergic agonists, does not involve cardiac beta adrenoceptors but baroreflex mechanisms. J Pharmacol Exp Ther 263:1083-1090.
26. Uehling DE, Shearer BG, Donaldson KH, Chao EY, Deaton DN, Adkison KK, Brown KK, Cariello NF, Faison WL, Lancaster ME, et al. (2006) Biarylaniline phenethanolamines as potent and selective β3 adrenergic receptor agonists. J Med Chem 49:2758-2771.
27. Woods M, Carson N, Norton NW, Sheldon JH, and Argentieri TM (2001) Efficacy of the β3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J Urol 166:1142-1147.
28. Yamaguchi O (2002) β3-Adrenoceptors in human detrusor muscle. Urology 59:25-29.
29. Yamanishi T, Chapple CR, Yasuda K, Yoshida K, and Chess-Williams R (2002) The role of β(3)-adrenoceptors in mediating relaxation of porcine detrusor muscle. Br J Pharmacol 135:129-134.
30. 3-adrenoceptor selective agonist, on relaxation of the human detrusor muscle in vitro. Neurourol Urodyn 25:815-819.
31. Yamazaki Y, Takeda H, Akahane M, Igawa Y, Nishizawa O, and Ajisawa Y (1998) Species differences in the distribution of beta-adrenoceptor subtypes in bladder smooth muscle. Br J Pharmacol 124:593-599.